PMID- 36437379
OWN - NLM
STAT- MEDLINE
DCOM- 20221129
LR  - 20230113
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Nov 27
TI  - Expression of HLA class I is associated with immune cell infiltration and patient 
      outcome in breast cancer.
PG  - 20367
LID - 10.1038/s41598-022-24890-3 [doi]
LID - 20367
AB  - Downregulation of human leukocyte antigen (HLA) class I is one mechanism of 
      escaping anti-tumor immunity by tumor cells. This study was conducted to compare 
      HLA class I expression in ductal carcinoma in situ (DCIS) and invasive breast 
      carcinoma (IBC) and to evaluate its association with immune cell infiltration of 
      the tumors and clinical outcome of the patients. A total of 830 cases comprising 
      288 DCIS and 542 IBC were included in this study. Immunohistochemistry for HLA 
      class I expression was performed using HLA-ABC in tissue microarrays and was 
      analyzed in relation to clinicopathologic characteristics of tumors and 
      infiltration of CD4+, CD8+, and FOXP3+ tumor-infiltrating lymphocyte (TIL) 
      subsets and PD-L1+ immune cells. As a whole, there was no difference in HLA class 
      I expression between DCIS and IBC when dichotomized into high or low expression. 
      However, in the HR-negative group, a high level of HLA class I expression was 
      more frequent in IBC than DCIS. On the contrary, in the HR-positive group, a 
      complete loss of HLA class I expression was more frequently observed in IBC than 
      DCIS. High HLA class I expression level was generally associated with aggressive 
      clinicopathologic features of IBC and was associated with high CD4+, CD8+, and 
      FOXP3+ TIL and PD-L1+ immune cell infiltration in both DCIS and IBC. In survival 
      analyses, HLA class I expression was not associated with clinical outcome in DCIS 
      and IBC as a whole; however, low HLA class I expression was associated with poor 
      clinical outcome in HR-negative IBC, especially in triple-negative subtype. In 
      conclusion, this study showed that HLA class I expression increased in 
      association with increased immune cell infiltration during in situ to invasive 
      transition of HR-negative breast cancer, and HLA class I down-regulation had a 
      prognostic value in HR-negative breast cancer.
CI  - (c) 2022. The Author(s).
FAU - Han, Song-Hee
AU  - Han SH
AD  - Department of Pathology, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
AD  - Department of Pathology, Dong-A University College of Medicine, Busan, Republic 
      of Korea.
FAU - Kim, Milim
AU  - Kim M
AD  - Department of Pathology, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
AD  - Department of Pathology, Seoul National University Bundang Hospital, 82, Gumi-Ro 
      173 Beon-Gil, Bundang-Gu, Seongnam, Gyeonggi, 13620, Republic of Korea.
FAU - Chung, Yul Ri
AU  - Chung YR
AD  - Pathology Center, Seegene Medical Foundation, Seoul, Republic of Korea.
FAU - Woo, Ji Won
AU  - Woo JW
AD  - Department of Pathology, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
AD  - Department of Pathology, Seoul National University Bundang Hospital, 82, Gumi-Ro 
      173 Beon-Gil, Bundang-Gu, Seongnam, Gyeonggi, 13620, Republic of Korea.
FAU - Choi, Hye Yeon
AU  - Choi HY
AD  - Department of Pathology, Seoul National University Bundang Hospital, 82, Gumi-Ro 
      173 Beon-Gil, Bundang-Gu, Seongnam, Gyeonggi, 13620, Republic of Korea.
FAU - Park, So Yeon
AU  - Park SY
AD  - Department of Pathology, Seoul National University College of Medicine, Seoul, 
      Republic of Korea. sypmd@snu.ac.kr.
AD  - Department of Pathology, Seoul National University Bundang Hospital, 82, Gumi-Ro 
      173 Beon-Gil, Bundang-Gu, Seongnam, Gyeonggi, 13620, Republic of Korea. 
      sypmd@snu.ac.kr.
LA  - eng
GR  - 02-2020-0043/Seoul National University Bundang Hospital/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221127
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Forkhead Transcription Factors)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Intraductal, Noninfiltrating/pathology
MH  - B7-H1 Antigen/metabolism
MH  - *Triple Negative Breast Neoplasms/metabolism
MH  - Lymphocytes, Tumor-Infiltrating
MH  - Histocompatibility Antigens Class I/metabolism
MH  - Forkhead Transcription Factors/metabolism
PMC - PMC9701770
COIS- The authors declare no competing interests.
EDAT- 2022/11/28 06:00
MHDA- 2022/11/30 06:00
PMCR- 2022/11/27
CRDT- 2022/11/27 23:26
PHST- 2022/05/03 00:00 [received]
PHST- 2022/11/22 00:00 [accepted]
PHST- 2022/11/27 23:26 [entrez]
PHST- 2022/11/28 06:00 [pubmed]
PHST- 2022/11/30 06:00 [medline]
PHST- 2022/11/27 00:00 [pmc-release]
AID - 10.1038/s41598-022-24890-3 [pii]
AID - 24890 [pii]
AID - 10.1038/s41598-022-24890-3 [doi]
PST - epublish
SO  - Sci Rep. 2022 Nov 27;12(1):20367. doi: 10.1038/s41598-022-24890-3.